IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re:	Patent Application of Doris Bell, *et al.*	: Group Art Unit: 1645
Appl. No.:	10/565,135	: Examiner: To be assigned
Filing Date:	December 18, 2006	: Confirmation No.:9061
For:	USE OF CIS-9, TRANS-11 ISOMER OF CONJUGATED LINOLEIC ACID (CLA) FOR TREATING INFLAMMATORY DISEASES	: Attorney Docket : No.: **C 2864 PCT/US**

Customer No.: 23657

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Transmitted herewith is an Information Disclosure Statement ("IDS") in the above-referenced application, together with an IDC form listing all references cited and a copy of each reference (unless the reference is a U.S. patent application).

Each item of information cited herein was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the mailing of this IDS, and no final action under 37 C.F.R. § 1.113 or notice of allowance under 37 C.F.R. § 1.311 has been received. Therefore, no fee for submitting this IDS is believed to be due. However, the Commissioner is hereby authorized to charge Deposit

Appl. No. : 10/565,135
Grp./A.U. : 1645

Account No. 50-1177 if any fee under 37 C.F.R. 1.17 is deemed necessary.

All the references are in English and/or are cited in an accompanying English language version of a search report by another patent office, so that comment on the references by the applicant is not required under 37 C.F.R. § 1.98(a).

Respectfully submitted,

John F. Daniels
(Reg. No. 34,314)
Attorney for Applicant(s)
215-628-1413

Cognis Corporation
Law Department
300 Brookside Avenue
Ambler, PA 19002

JFD/mc H:\IDC\C2864ids.doc

Enclosure
1. EP Communication
2. IDC w/references